Viking Therapeutics, Inc. (VKTX)
After hours:
| Previous Close | 50.77 |
| Open | 51.25 |
| Bid | 52.93 x 400 |
| Ask | 53.06 x 800 |
| Day's Range | 51.05 - 54.80 |
| 52 Week Range | 8.28 - 99.41 |
| Volume | |
| Avg. Volume | 3,421,865 |
| Market Cap | 5.845B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings Date | Jul 24, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 113.36 |
Insider MonkeyWhat Makes Viking Therapeutics, Inc. (VKTX) One of the Best Healthcare Stocks to Buy Under $50?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the other healthcare stocks under $50. If interested, you can also read our recent article on the 10 Best Healthcare Stocks To […]
ZacksViking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.
PR NewswireViking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. The presentation highlights the effects of treatment on body weight, food intake and metabolic profile in h
